Hidradenitis suppurativa treated with finasteride.

Hidradenitis suppurativa (HS) remains a challenging condition with limited effective treatment options. Prior research has shown that hormonal factors, particularly those involving androgen metabolism, may play a role in HS pathogenesis. It was already known that 5α-reductase converts testosterone to dihydrotestosterone, a hormone linked to skin inflammation. No prior work had resolved how blocking this enzyme might affect HS. This gap motivated a search for alternative therapies targeting hormonal pathways. Existing treatments like antibiotics often fail to provide long-term relief. That uncertainty drove the need for new approaches beyond traditional antibiotics. This paper's contribution is a preliminary exploration of finasteride's potential in HS management.

This study aimed to assess whether finasteride, a type II 5α-reductase inhibitor, could offer a new treatment option for HS. The specific problem addressed is the lack of long-term efficacy in current therapies. The motivation stems from prior evidence linking androgen activity to HS. The researchers propose that reducing dihydrotestosterone levels may alleviate symptoms. This approach was chosen because 5α-reductase inhibition had not been widely tested for HS. The goal was to evaluate both effectiveness and tolerability in a small patient group. The study focused on patients who had not responded to antibiotics. The researchers aimed to determine if finasteride could induce remission in HS.

The study involved seven patients with HS who had not responded to antibiotics. Finasteride was administered at a dose of 5 mg/day as monotherapy. Clinical assessments were conducted at regular intervals. Patients were observed for durations ranging from 8 months to 2 years. The primary outcome was clinical improvement, measured through lesion healing. Secondary outcomes included duration of remission and adverse effects. The study design was observational and not randomized. The researchers collected data on lesion resolution and patient-reported side effects.

Six out of seven patients showed significant improvement in HS symptoms. Three patients achieved complete healing of lesions. Two patients experienced remissions lasting 8–18 months. The drug was generally well tolerated by the study participants. Two women reported breast enlargement as a side effect. No other serious adverse events were recorded during the follow-up period. The longest follow-up period was 2 years for some patients. These findings suggest finasteride may offer therapeutic benefit in HS.

The authors propose that finasteride may be an effective treatment for HS based on the observed clinical responses. The findings suggest that 5α-reductase inhibition could be a viable therapeutic approach. The results are consistent with the hypothesis that androgen activity contributes to HS. The study supports further investigation into finasteride's role in HS treatment. The authors do not claim that finasteride is essential for HS management. The observed remissions indicate potential for long-term symptom control. The drug's tolerability supports its use in HS patients. These conclusions are limited to the small sample and short follow-up period.